New Research Suggests Potential for Additional Clinical Utility of QIAGEN's QuantiFERON-TB Gold Plus

HILDEN, Germany, and GERMANTOWN, Maryland, April 12, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that two peer-reviewed studies indicate the potential additional clinical value for QuantiFERON-TB^® Gold Plus (QFT-Plus^®), the fourth-generation test using enhanced QuantiFERON technology to detect latent tuberculosis (TB) infection. Both studies focus on potential benefits of novel CD8+ T-cell stimulating antigens contained in QFT-Plus. A study at the Stanford University School of Medicine is the first publication describing the performance of QFT-Plus in healthcare workers, while a study at Japan's National Hospital Organization Hokkaido Medical Center provides the first evidence for QFT-Plus as a potential monitoring aid during treatment of active TB.

"These studies add to a growing body of clinical evidence on QuantiFERON-TB Plus, suggesting added utility for our novel CD8+ T-cell technology. We have introduced QFT-Plus in more than 60 markets since 2015 to aid in tuberculosis control by screening at-risk populations for latent TB infection," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. "The unique ability of QFT-Plus to measure CD8+ immune response has led the World Health Organization to suggest that the new test offers potential for identifying patients at greater risk of progressing to active TB. A number of clinical studies are underway to explore broader applications based on the CD8+ capability, although regulatory approvals to date focus on the effectiveness of QFT-Plus in detecting latent TB infection."

Click here for the full press release

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={C6C448EE-E2CE-440C-A18E-ED5EA0226D34}&lang=en

Contacts: 
QIAGEN 
Investor Relations
John Gilardi: +49-210-3291-1711
e-mail: ir@QIAGEN.com   

Public Relations
Dr. Thomas Theuringer: +49-210-3291-1826
e-mail: pr@QIAGEN.com

SOURCE QIAGEN N.V.